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Summary
BACKGROUND: Continuous EEG (cEEG) is increasingly
used in critically ill patients, but it is more resource-inten-
sive than routine EEG (rEEG). In the US, cEEG generates
increased hospitalisation charges. This study analysed
hospital-related reimbursement for participants in a Swiss
multicentre randomised controlled trial that assessed the
relationship of cEEG versus repeated rEEG with outcome.
METHODS: We used data of the CERTA study
(NCT03129438), including demographics, clinical vari-
ables and reimbursement for acute hospitalisations after
the Swiss Diagnosis Related Groups billing system. In ad-
dition to a comparison between EEG intervention groups,
we explored correlations with several clinical variables, us-
ing uni- and multivariate analyses.
RESULTS: In total, 366 adults were analysed (184 cEEG,
182 rEEG); 123 (33.6%) were women, mean age was
63.8 years (± 15). Median hospitalisation reimbursement
was comparable across EEG groups in univariate analy-
sis: cEEG CHF 89,631 (interquartile range [IQR]
45,635–159,994); rEEG CHF 73,017 (IQR
43,031–158,565); p = 0.432. However, multivariate re-
gression disclosed that increasing reimbursement mostly
correlated with longer acute hospitalisation (p <0.001), but
also with cEEG (p = 0.019) and lack of seizure / status
epilepticus detection (a surrogate of survival, p = 0.036).
CONCLUSION: In a Swiss Diagnosis Related Groups
billing system applied to critically ill adults, reimbursement
largely depends on duration of acute hospital stay, where-
as cEEG and lack of seizure/ status epilepticus detection
also contribute to the bill. This differs from the USA, where
charges are directly increased by cEEG.
Introduction
Continuous electroencephalographic monitoring (cEEG,
typically lasting several hours to a few days) is increas-
ingly used to assess brain function and identify epilepti-
form activity in patients with unexplained consciousness
impairment in intensive care units (ICUs). In fact, cEEG
is more sensitive for seizure or status epilepticus detection
than routine EEG (rEEG, typically lasting 20–30 minutes)
[1–3]. Several international guidelines strongly recom-
mend its use in critically ill patients [4, 5]. However, cEEG
is resource- and time-consuming compared with rEEG; it
requires longer review times, constant machine availabili-
ty and surveillance by skilled personnel [3, 6]. Therefore,
its widespread clinical adoption is hampered in many hos-
pitals, including most European centres [7].
In addition to these logistics issues, in the USA cEEG
is related to higher hospitalisation charges compared with
rEEG [6, 8, 9]; that hospital reimbursement system never-
theless differs from those of other settings, since different
professional fees are applied to EEG procedures. Several
European countries including Switzerland [10, 11], Aus-
tralia, Canada and Japan [12] use diagnosis-related groups
(DRGs), whose purpose is to classify patients according
to demographics, principal and secondary diagnoses, co-
morbidities and complications; procedures performed play
a relatively minor role. Based on this information, patients
will belong to a certain DRG [13] associated with a spe-
cific reimbursement estimated on similar cases [11]. DRGs
are also used in the USA, but underlying charges related to
equipment, technologists and physicians increase the over-
all cost of care [14], inducing higher prices [1, 9].
In the context of optimisation of hospital resources, it is
important to assess the value of healthcare delivery con-
cerning the consequences on patient care and prognosis
[15]. Impact of cEEG versus rEEG on clinical outcome has
been recently assessed in a multicentre Swiss randomised
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controlled trial in adults with acute consciousness impair-
ment [16]. The primary purpose of the present study was
to analyse the impact of these procedures on hospitalisa-
tion reimbursement. In Switzerland, professional fees ac-
cording to specific in-hospital procedures are not foreseen,
and the DRG-based hospital reimbursement is paid by the
patient’s insurance and a contribution of the state (canton).
Methods
Population, variables and outcomes
We used data from the Continuous EEG Randomized Trial
in Adults (CERTA, NCT03129438), conducted in four
large Swiss hospitals (Centre Hospitalier Universitaire
Vaudois in Lausanne, Inselspital Bern, Universitätsspital
Basel, and Hôpital de Sion, the only non-university centre)
between April 2018 and September 2019; 366 patients
were analysed, exceeding the required sample size [16].
Of them, 30.1% had hypoxic-ischaemic encephalopathy,
23.8% intracranial haemorrhage, 13.4% brain trauma. Pa-
tients aged ≥18 years, presenting an alteration of con-
sciousness of any aetiology with a Glasgow Coma Scale
score ≤11 or a Full Outline of UnResponsiveness (FOUR)
score ≤12, and needing an EEG either to exclude seizures
or status epilepticus, or to evaluate prognosis, were ran-
domised – upon investigator availability – 1:1 to cEEG
(30–48 hours) or two rEEGs (20–30 minutes each, within
30–48 hours) [3, 16]. Several demographic and clinical
variables were recorded prospectively; the detailed proto-
col may be found in a link from the principal publication
[16].
For the present study, we considered demographics and
the three most frequent aetiologies of consciousness im-
pairment in the CERTA study, and retrieved information
about the reimbursement for each participant due to acute
hospitalisation, in each participating institution; this was
routinely calculated according to the Swiss DRGs. We
also explored different variables, such as occurrence of
any EEG-triggered changes in clinical patient management
(anti-seizure medications introduced or stopped, anti-
seizure medications increased or decreased, brain imaging
procedure order) during 60 hours following the start of
the first EEG [16], mortality at 6 months, seizure or status
epilepticus detection rate, duration of hospitalisation, and
reimbursement related to the two EEG procedures.
Statistical analysis
In addition to crude reimbursement comparisons (in CHF)
between the EEG intervention groups, we explored cor-
relations with clinical variables. Mann-Whitney U-tests
or chi-square tests were used as appropriate. Spearman’s
rank coefficients were applied to assess correlations be-
tween reimbursement and continuous variables (age, dura-
tion of acute hospital stay). Tests with a p-value <0.05 were
considered statistically significant. A stepwise multivariate
linear regression was applied to identify variables indepen-
dently related to reimbursement among those that resulted
statistically significant in univariate analyses, including al-
so EEG intervention in view of the existing literature. Ef-
fect size was estimated using partial eta squares. Calcula-
tions were made using Stata 16 (College Station, TX).
Ethics
This study was approved by the CER-VD ethics commis-
sion and was conducted in accordance with the Helsin-
ki declaration. Recruited patients (or their parents or
guardians) gave their written informed consent.
Results
A total of 366 critically ill patients were analysed, of whom
184 underwent cEEG and 182 rEEG. There were 123
(33.6%) women, with a mean age of 63.8 years (standard
deviation [SD] 15.0); 177 (48.4%) patients died. Distri-
bution of the major aetiologies (anoxic-ischaemic en-
cephalopathy, intracranial haemorrhage, brain trauma) was
not different between recruiting sites (p = 0.163, χ2).
Median acute hospitalisation reimbursement seemed
somewhat higher in patients undergoing cEEG (CHF
89,631, interquartile range [IQR] 45,635–159,994) than
those randomised to rEEG (CHF 73,017, IQR
43,031–158’565); however, this difference was not signifi-
cant (p = 0.432, U-test). Table 1 shows further analyses for
the global cohort, stratified by EEG intervention. In uni-
variate analyses of the whole cohort, increasing amounts
strongly correlated with lack of hypoxic-ischaemic en-
cephalopathy, intracranial haemorrhage, lack of changes
in clinical management within 60 hours, no detection of
seizure/status epilepticus, and survival at 6 months, as well
as younger age (rho –0.177, p <0.001, Spearman), and
longer acute hospitalisation (rho 0.77, p <0.001, Spear-
man); figure 1 shows the distribution stratified by EEG in-
tervention. Conversely, no association was found between
reimbursement and gender, hospital, or brain trauma (table
1). Stratification by EEG intervention also did not reveal
any significant difference.
Median acute hospitalisation was longer in surviving pa-
tients than those who were deceased (41 days, IQR 14–53
vs 10 days, IQR 5–23; p <0.001) and patients undergoing
rEEG (19 days, IQR 9–37 vs 16 days, IQR 7 – 42; p =
0.012); it was shorter in those having changes in clinical
management (12 days, IQR –31 vs 20 days, IQR 10–45;
p <0.001), who had hypoxic-ischaemic encephalopathy (9
days, IQR 4–24 vs 22 days IQR 11–43; p <0.001), or had
seizures or status epilepticus detected (9 days, IQR 5–27
vs 19 days, IQR 9–42; p = 0.003; all U-tests). Patients had
higher mortality if having clinical management changes
(62.8% vs 38.9%, p <0.001), if they had anoxic-ischaemic
Figure 1: correlation of reimbursement and duration of acute hos-
pitalisation stratified for cEEG (left; rho 0.817, p <0.001) and rEEG
(right; rho 0.729, p <0.001).
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encephalopathy (60.7% vs 42.9%, p = 0.002), or if
seizures/status epilepticus were detected (81.1% vs 44.7%,
p <0.001), whereas presence of intracranial haemorrhage
was not significant (p = 0.317; all χ2), as the EEG interven-
tion [16].
In order to assess the relative interplay of the different vari-
ables of interest regarding reimbursement, we performed
a multivariate linear regression including including EEG
intervention and variables that resulted significant in uni-
variate analyses (table 1). Aetiology, change in clinical
management and mortality were not significant, whereas
duration of acute hospitalisation duration (t = 10.74, p
<0.001), cEEG (t = 2.35, p = 0.019) and no detection of
seizures/status epilepticus (t = 2.10, p = 0.036) were in-
dependently related to higher reimbursement. In particular,
EEG intervention was significant only when considering
hospitalisation length, and effect size estimation (partial
eta squares) showed the strong contribution of hospitali-
sation duration (0.261), compared with cEEG (0.015) and
seizure/status epilepticus detection (0.012).
Discussion
This study in a Swiss DRG billing environment shows that
cEEG has a higher reimbursement than rEEG in critically
ill adults; this is, however, not directly evident and can be
identified only after considering duration of acute hospital-
isation, which in turn represents by far the main cost deter-
minant.
To our knowledge, no European study has addressed this
question to date, and this represents the first analysis based
on a randomised controlled trial. It is intriguing to observe
that EEG length did not correlate with reimbursement in
univariable analysis, and thus at first glance may not gener-
ate any direct financial incentive to perform cEEG record-
ings; its role appeared only together with hospitalisation
duration (and, to a lesser extent, no detection of seizures /
status epilepticus). This illustrates the really complex inter-
play between these variables: as ictal events are more fre-
quently identified in patients undergoing cEEG [16], these
two variables have opposite influences on reimbursement,
which is mostly determined by hospitalisation length.
While patients undergoing cEEG tend to have shorter hos-
Table 1: Reimbursement and variables of interests (for the whole cohort, and stratified by EEG intervention group). Numbers represent medians (and interquartile range). Bold
numbers are significant (Mann-Whitney U-tests).
Variable Acute hospitalisation reim-
bursement (CHF)




0.164 91,212 (46,714–162,952) 84,691 (46,045–171,972) 0.895
Others (77) 73,964.75
(39,786–130,988)




0.322 86,731 (44043–148,388) 70,908 (40,782–146,598) 0.460
Male (243) 87,437
(45,702 - 165,717)




< 0.001 53,188 (30,210–111,904) 59,057 (30,915–135,033) 0.624
No (254) 97,264
(54,068–172,433)
106,790 (60,058–181,368) 87,511 (52,391–171,574) 0.112
Intracranial haemorrhage
Yes (87) 108,968 (62,548–172,433) 0.012 98,306 (64,918–168,184) 115,005 (61,379–176,922) 0.304
No (279) 80,863
(38,221–153,038)




0.380 86,412 (59,026–156,613) 100,467 (60,210–138,770) 0.737
No (317) 83,429
43,260–162,221
92,650 (43,772 162,758) 72,069 (42,932–162,221) 0.554
Diagnosis of seizures/status epilepticus
Yes (37) 55,456
(30,216–119,899)
0.006 55,456 (30,901–100,831) 51,385 (20,077–156,310) 0.824
No (329) 87,437
(46,046–168,184)
100,473 (47,133–174,866) 75,251 (45,182–158,565) 0.167




0.002 67,974 (33,846–144,853) 63,726 (37,578–134,401) 0.813
No (221) 92,138
(52,930–171,972)
101,050 (61,728–174,866) 88,288 (46,148–162,221) 0.246
Outcome at 6 months
Death (177) 65,161
(36,560–129,293)
<0.001 68,049 (34,521–129,203) 62,716 (37,578–133,486) 0.851
Survival (189) 108,968
(54,068–181,312)
112,205 (61,728–183,950) 100,041 (51,328–175,412) 0.461
CHUV = Centre Hospitalier Universitaire Vaudois; EEG = electroencephalography
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pitalisations (tending to lower costs, see below), adjusting
for hospitalisation length probably unravels the cEEG con-
tribution. In turn, seizure/status epilepticus detection likely
acts as a mortality surrogate (and thus shorter hospitalisa-
tion and lower costs). Our results, generated by a DRG sys-
tem apparently similar to those used in several other set-
tings, including many European countries, where a specific
procedure’s cost is “diluted” into the diagnostic group, dif-
fer from US studies, where the cEEG billing system leads
to higher charges that are readily recognisable, without
need for adjustments [9, 15].
Higher mortality was related to shorter hospitalisation,
therefore inducing lower reimbursements. This applied to
patients with anoxic-ischaemic encephalopathy, or in
whom seizures / status epilepticus were detected, or clini-
cal management was modified.
Our results should be interpreted in the context of some
limitations. Firstly, the relatively low number of patients in
each group, particularly after stratification for EEG inter-
vention, might reduce statistical power (the CERTA study
was designed to detect a difference in survival between
EEG intervention groups, not this secondary endpoint).
Secondly, our data were generated in Switzerland; never-
theless, several other countries use DRGs and we believe
that our findings may apply to them as well. Third, this
study was not designed to estimate the specific costs gen-
erated by the detection (or not) of seizures/status epilepti-
cus. On the other hand, one of the study strengths is the
multicentre randomised design to assign cEEG or rEEG.
Also, since DRGs are used as a national billing system in
Switzerland, internal validity should be preserved; indeed,
no significant difference was found across recruiting cen-
tres. Application of multivariable analyses allowed a rela-
tively refined understanding of the different parameters re-
lated to the final bill. Furthermore, inclusion of patients in
university and non-university hospitals supports generalis-
ability of our results.
In a European DRG-based billing system applied to criti-
cally ill adults, reimbursement depends mostly on duration
of acute hospital stay, whereas use of cEEG and lack of
seizures / status epilepticus detection also play a role. This
differs from the USA billing system, where the impact of
cEEG on hospitalisation charges appears more direct.
Data availability
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quest.
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